Holen Sie sich die Stockscreener-App
4.34
2.94%
0.124
Schlusskurs vom Vortag:
$4.216
Offen:
$4.24
24-Stunden-Volumen:
68,973
Relative Volume:
0.26
Marktkapitalisierung:
$13.36M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-0.2837
EPS:
-15.2954
Netto-Cashflow:
$-24.23M
1W Leistung:
+0.70%
1M Leistung:
+1.17%
6M Leistung:
-74.27%
1J Leistung:
-86.33%
1-Tages-Spanne:
$4.1001
$4.40
1-Wochen-Bereich:
$4.03
$4.40
52-Wochen-Spanne:
$3.13
$69.50
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.34 | 12.98M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Why Moleculin Biotech Inc. stock remains on buy listsQuarterly Profit Report & AI Driven Stock Price Forecasts - mfd.ru
What’s the profit margin of Moleculin Biotech Inc.Trade Analysis Report & High Win Rate Trade Alerts - mfd.ru
Moleculin Launches CEO Corner Platform to Share Strategic Insights - Finviz
Moleculin launches CEO Corner to enhance investor communication By Investing.com - Investing.com Nigeria
Can Moleculin Biotech Inc. benefit from deglobalizationJuly 2025 Final Week & Weekly Stock Breakout Alerts - mfd.ru
Moleculin Biotech (MBRX) Unveils CEO Corner for Investor Insights - GuruFocus
New Moleculin CEO Corner invites investor questions on trials, strategy - Stock Titan
Moleculin at Corporate Connect: Annamycin’s Promising Future By Investing.com - Investing.com Canada
Moleculin Biotech: Annamycin's Phase 3 trial nears key data, with strong efficacy and major market potential - TradingView
Moleculin Biotech: Annamycin's phase 3 trial in AML offers near-term data and major market potential - TradingView
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech stockholders approve warrant issuance, reject name change By Investing.com - Investing.com Australia
Moleculin Biotech stockholders approve warrant issuance, reject name change - Investing.com
Moleculin Biotech Shareholders Approve Warrant Share Issuance - TipRanks
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - marketscreener.com
Aug Final Week: Is MNDO a play on infrastructure spending2025 Technical Patterns & Real-Time Market Sentiment Reports - baoquankhu1.vn
AI Stocks: Can Moleculin Biotech Inc maintain sales growth2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
What are Home Bancshares Inc. (Conway AR)’s growth leversMarket Risk Analysis & Fast Moving Stock Trade Plans - baoquankhu1.vn
Aug Intraday: Can Moleculin Biotech Inc maintain sales growthTrade Ideas & High Accuracy Swing Trade Signals - baoquankhu1.vn
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference - intellectia.ai
Will Moleculin Biotech Inc. benefit from geopolitical trendsRate Hike & Smart Investment Allocation Insights - mfd.ru
Moleculin Biotech Updates Investors with New Corporate Presentation - TipRanks
Aug Spikes: What are Moleculin Biotech Incs earnings expectations2025 Geopolitical Influence & Safe Entry Zone Identification - baoquankhu1.vn
New brain cancer trial tests WP1066 plus radiation in glioblastoma - Stock Titan
MBRXMoleculin Biotec Latest Stock News & Market Updates - Stock Titan
Moleculin’s Annamycin shows no cardiotoxicity in cancer trials By Investing.com - Investing.com Nigeria
Moleculin’s Annamycin shows no cardiotoxicity in cancer trials - Investing.com
Moleculin Highlights Non-Cardiotoxic Profile of Lead Annamycin Drug - TipRanks
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects - The Manila Times
Moleculin Biotech, Inc. Reports No Cardiotoxicity in Annamycin Trials - TradingView — Track All Markets
Moleculin Biotech, Inc. Reports No Evidence of Cardiotoxicity for Annamycin Across Five Clinical Trials - Quiver Quantitative
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - MSN
Moleculin expects first MIRACLE trial data readout in Q1 2026 By Investing.com - Investing.com Nigeria
Moleculin Biotech (MBRX) Readies Annamycin for Major Milestones in 2026 - GuruFocus
Moleculin expects first MIRACLE trial data readout in Q1 2026 - Investing.com
Moleculin Biotech advances Annamycin AML Phase 3 program - TipRanks
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs - The Manila Times
Moleculin Biotech, Inc. Announces Milestones and Upcoming Unblinding for MIRACLE Trial in Acute Myeloid Leukemia and New Pancreatic Cancer Initiatives - Quiver Quantitative
Moleculin accelerates outlook into 2026 with first pivotal trial unblinding on track, global trial expansion, and multiple externally/IIT funded clinical programs - marketscreener.com
Moleculin Biotech, Inc. Accelerates 2026 Outlook with Key Clinical Trials - TradingView
Experimental chemo aiming to spare the heart nears key 2026 trial test - Stock Titan
Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Buy Signal: Why Moleculin Biotech Inc. stock could rally in 20252025 Stock Rankings & Weekly Chart Analysis and Trade Guides - Улправда
What technical charts say about Moleculin Biotech Inc. stockGap Up & Reliable Breakout Stock Forecasts - Улправда
Why retail investors favor Moleculin Biotech Inc. stockEarnings Miss Alerts & Free Fast Track Wealth Growth - ulpravda.ru
Moleculin Biotech, Inc.Common Stock (Nasdaq:MBRX) Stock Quote - FinancialContent
Why Moleculin Biotech Inc. stock is considered a top pickMarket Insider Reports & Budget Friendly Trading Strategies - Улправда
Moleculin Biotech regains Nasdaq listing compliance - marketscreener.com
Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - TipRanks
Moleculin Biotech Regains Nasdaq Compliance - TradingView
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moleculin Biotech Inc-Aktie (MBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):